Episode Details
Back to EpisodesWeekly Headlines: Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap
Published 1 year, 9 months ago
Description
Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap • Lensar Receives European Approval for ALLY System • Lenz Therapeutics Submits NDA for Presbyopia Eye Drop
Learn more about your ad choices. Visit megaphone.fm/adchoices